HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 478 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... June 15, 2022 FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma January 25, 2021 EMA Recommends Extension of Therapeutic Indications for Teclistamab September 11, 2026 Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian September 4, 2026 Load more HOT NEWS Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... Building Your Fort of Support: Tips from a Breast Cancer Social... Honoring Other’s Wishes Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in...
